ERIS Lifesciences Ratios

ERIS Lifesciences Ltd Ratios

The ERIS Lifesciences Ltd Ratios page provides a complete fundamental analysis of ERIS Lifesciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking ERIS Lifesciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

ERIS Lifesciences Ltd (NSE: ERIS, BSE: 540596) is currently trading at ₹1358.30, with a market capitalization of ₹185.15B. As a major player in the Health technology sector and Pharmaceuticals: major industry, ERIS Lifesciences Ltd remains a key stock for fundamental analysis using ERIS Lifesciences Ltd Ratios.

ERIS Lifesciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The ERIS Lifesciences Ltd P/E ratio currently stands at 54.87, making it one of the most tracked metrics in ERIS Lifesciences Ltd Ratios.

Historically, the ERIS Lifesciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 54.87
• 2023: 29.22
• 2022: 20.38
• 2021: 23.06
• 2020: 23.13

The rising ERIS Lifesciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The ERIS Lifesciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 6.76.

Historical P/B trend:

• 2024: 6.76
• 2023: 4.42
• 2022: 3.54
• 2021: 4.91

ERIS Lifesciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The ERIS Lifesciences Ltd P/S ratio currently stands at 6.67, an important part of ERIS Lifesciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 6.67
• 2023: 5.70
• 2022: 4.62
• 2021: 6.95

The rising ERIS Lifesciences Ltd P/S ratio indicates improved revenue valuation by investors.

ERIS Lifesciences Ltd Price to Cash Flow Ratio (P/CF)

The ERIS Lifesciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.89.

Historical ERIS Lifesciences Ltd Price to Cash Flow Ratio:

• 2024: 20.89
• 2023: 27.55
• 2022: 28.60
• 2021: 24.68
• 2020: 21.91

The declining ERIS Lifesciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

ERIS Lifesciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The ERIS Lifesciences Ltd EV currently stands at ₹219.77B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 219.77B
• 2023: 134.71B
• 2022: 86.02B
• 2021: 92.36B

ERIS Lifesciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The ERIS Lifesciences Ltd EV/EBITDA ratio is currently 21.35, a key metric in ERIS Lifesciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 21.35
• 2023: 19.22
• 2022: 15.74
• 2021: 18.62

Higher ERIS Lifesciences Ltd EV/EBITDA suggests premium valuation.

ERIS Lifesciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The ERIS Lifesciences Ltd D/E ratio is currently 0.87, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.87
• 2023: 1.08
• 2022: 0.40
• 2021: 0.04

ERIS Lifesciences Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The ERIS Lifesciences Ltd ROE currently stands at 12.93%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 12.93
• 2023: 16.40
• 2022: 18.62
• 2021: 23.31

ERIS Lifesciences Ltd maintains stable profitability levels.

ERIS Lifesciences Ltd Ratios Analysis Summary

The ERIS Lifesciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether ERIS Lifesciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking ERIS Lifesciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.